Table 1.
Clinicopathologic features of the DCIS, mIDC, and IDC lesions in the study cohort
| DCIS (n = 112) | mIDC (n = 50) | IDC (n = 44) | P value | |
|---|---|---|---|---|
| Age, years | 48.6 ± 10.3 | 50.3 ± 11.5 | 52.1 ± 10.8 | 0.181 |
| Biopsy method | 0.028 | |||
| SVAB | 28 (25.0) | 6 (12.0) | 4 (9.1) | |
| US-CNB | 84 (75.0) | 44 (88.0) | 40 (90.9) | |
| Surgery type | < 0.001 | |||
| Breast conserving | 80 (71.4) | 29 (58.0) | 15 (34.1) | |
| Mastectomy | 32 (28.6) | 21 (42.0) | 29 (65.9) | |
| Nuclear grade | 0.001 | |||
| 1 | 15 (13.4) | 4 (8.0) | 1 (2.3) | |
| 2 | 88 (78.6) | 30 (60.0) | 29 (65.9) | |
| 3 | 9 (8.0) | 16 (32.0) | 14 (31.8) | |
| Necrosis | 0.073 | |||
| Present | 54 (47.4) | 33 (66.0) | 27 (61.4) | |
| Absent | 58 (51.8) | 17 (34.0) | 17 (38.6) | |
| Pathologic tumor size (cm) | 2.0 ± 1.6 | 3.7 ± 2.3 | 4.5 ± 2.4 | < 0.001 |
| Estrogen receptor | < 0.001 | |||
| Positive | 103 (92.0) | 26 (52.0) | 34 (77.3) | |
| Negative | 9 (8.0) | 24 (48.0) | 10 (22.7) | |
| Progesterone receptor | < 0.001 | |||
| Positive | 95 (84.8) | 21 (42.0) | 26 (59.1) | |
| Negative | 17 (15.2) | 29 (58.0) | 18 (40.9) | |
| HER2 | < 0.001 | |||
| Positive | 20 (17.9) | 30 (60.0) | 16 (36.4) | |
| Negative | 92 (82.1) | 20 (40.0) | 28 (63.6) | |
| Ki-67 | < 0.001 | |||
| High (≥20%) | 24 (21.4) | 24 (48.0) | 24 (54.5) | |
| Low (< 20%) | 88 (78.6) | 26 (52.0) | 20 (45.5) |
Data values indicate the number of patients (with percentages in parentheses), or the mean ± standard deviation.
DCIS ductal carcinoma in situ; mIDC microinvasive ductal carcinoma; IDC invasive ductal carcinoma; SVAB stereotactic vacuum-assisted biopsy; US-CNB US-guided core needle biopsy; HER2 human epidermal growth factor receptor 2